Palatin Technologies Inc. (PTN)
Symbol Info
Listed Symbol PTN
Name Palatin Technologies Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2019-06-30
Latest Fiscal Revenue $60,300,476
Latest Fiscal EPS $0.16
Price Info
21 Day Moving Average $0.8653
21 Day EMA $0.864760
50 Day Moving Average $0.9045
50 Day EMA $0.908880
200 Day EMA $0.983970
200 Day Moving Average 1.002600
52 Week High $1.78
52 Week Low $0.59
52 Week Change $-10.002200
Alpha 0.012719
Beta 1.8256
Standard Deviation 0.221067
R2 0.080430
Periods 60
Share Information
10 Day Average Volume 667,126
20 Day Average Volume 921,629
30 Day Average Volume 1,345,492
50 Day Average Volume 1,136,555
Outstanding Shares 227,039,363
Float Shares 211,733,134
Percent Float 93.26%
Short Interest 24,843,229
Short Percent Float 10.90%
Short Interest Ratio 16.04
Short Date 2019-09-30
Holders
Institutions 162
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 4,723,461
Institute Holdings Percent 32.400000
Institute Sold Previous 3 Months 4,022,105
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 28
Insider Holdings Percent 7.10%
Insider Sold Previous 3 Months -
Insiders Shares Owned 15,306,229
Price Change
7 Day Price Change $0.0062000
7 Day Percent Change 0.75%
21 Day Price Change $-0.0551
21 Day Percent Change -6.21%
30 Day Price Change $-0.1151
30 Day Percent Change -12.15%
Month To Date Price Change $-0.0765
Month To Date Percent -8.42%
90 Day Price Change $-0.1623
90 Day Percent Change -16.32%
Quarter To Date $-0.0765
Quarter To Date Percent -8.42%
180 Day Price Change $-0.2277
180 Day Percent Change -21.48%
200 Day Price Change $-0.1677
200 Day Percent Change -16.77%
Year To Date $0.123900
Year To Date Percent 17.49%
Profile
Description Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Details
Issue Type CS
Market Cap $188,964,862
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 227,039,363
CEO Carl Spana
Employees 18
Last Audit UE
Classification
CIK 0000911216
Industry Medical Diagnostics & Research
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 4B Cedar Brook Drive
Cranbury, NJ 8512
Website https://www.palatin.com
Facisimile +1 609 495-2202
Telephone +1 609 495-2200
Email investors@palatin.com
Key Ratios
Profitability
EBIT Margin 60.00
EBITDA Margin 60.1
Pre-Tax Profit Margin -
Profit Margin Cont 68.79
Gross Margin -
Profit Margin TOT 68.79
Income Statements
Revenue $60,265,971
Revenue Per Share $0.2654
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio 5.40
Enterprise Value $163,155,887
Price To Sales 3.135515
Price To Free Cash -12.1
PE High Last 5 Years -
Price To Book 2.0
Price To Cash Flow 109.4
PE Low Last 5 Years -
Price To Tangible Book 2.0
Financial Strength
Total Debt To Equity -
Int Coverage 86.7
Current Ratio 24.9
Leverage Ratio 1.1
Quick Ratio 24.8
Long Term Debt To Capital -
Assets
Receivables Turnover 2.0
Invoice Turnover -
Assets Turnover 0.50
Management Effectiveness
Return Assets 49.77
Return On Equity 56.11
Return On Capital 54.10
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
AMEX
PTN
Palatin Te..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.